Back to results
US 2025/0051393 A1Published application
Compositions and methods for modulating interferon regulatory factor-5 (irf-5) activity
AssigneeEntrada Therapeutics, Inc.
InventorsZiqing QIAN, Natarajan SETHURAMAN, Mahboubeh KHEIRABADI, Haoming LIU, Xiulong SHEN, Xiang LI
Life of this patent
Estimating the term…
Abstract
Compounds that include a cyclic cell penetrating peptide and a therapeutic moiety modulates Interferon Regulatory Factor-5 (IRF-5) activity in an immune cell. The therapeutic moiety is a therapeutic protein, a small molecule, or an antisense compound. Methods include administering the compound to cells or subjects to modulate IRF-5 activity. Methods include treating diseases associated with IRF-5 using the compounds.
Claims22
1-129. (canceled)
A compound comprising:
- (a) a cyclic cell penetrating peptide of the formula:
- or a protonated form or salt thereof, wherein:
- R1, R2, and R3 are each independently H or an aromatic or heteroaromatic side chain of an amino acid;
- at least two of R1, R2, and R3 are the side chain of phenylalanine;
- R4 and R7 are independently H or an amino acid side chain;
- each m is independently an integer from 0 to 3;
- AASC is an amino acid side chain;
- and
- q is 1, 2, 3, or 4;
- (b) an exocyclic peptide comprising from 2 to 10 amino acid residues, wherein 2, 3, or 4 of the residues are lysine residues;
- (c) a linker of formula:
- wherein:
- x′ is an integer from 1-23;
- y is an integer from 1-5;
- z′ is an integer from 1-23;
- * is the point of attachment to the AASC of the cyclic peptide;
- and M is a bonding group;
- (d) an oligonucleotide that modulates Interferon Regulatory Factor-5 (IRF-5) activity, the oligonucleotide comprising an antisense compound complementary to a target nucleotide sequence encoding IRF-5.
15 more elements
Dependencies are inferred from the claim text.